Paediatric Presentation of Type 2 Neurofibromatosis

Overview

Journal Arch Dis Child

Specialty Pediatrics

Date 1999 Nov 26

PMID 10569966

Citations 41

Authors

D G Evans

J M Birch

R T Ramsden

Affiliations

Soon will be listed here.

Abstract

Background: Neurofibromatosis type 2 (NF2) is a highly penetrant autosomal dominant condition predisposing affected individuals to schwannomas and meningiomas. The proportion of children presenting with meningioma or schwannoma who have NF2 is not well described, and neither is the mode of presentation in most children with the inherited disease.

Aims: To determine the frequency of childhood meningioma and schwannoma cases caused by NF2 and the mode of presentation.

Methods: The records of the Manchester Children's Tumour Registry from 1954 were searched for cases of meningioma and schwannoma. Paediatric presentation in a large UK series of NF2 was also studied.

Results: 18% (61/334) of patients with NF2 on the UK database presented in the paediatric age group (0-15 years), frequently with the symptoms of an isolated tumour. More than half had no family history to alert the clinician to their susceptibility. Three of 22 children presenting with a meningioma on the Manchester Children's Tumour Registry have gone on to develop classic features of NF2.

Conclusions: Clinicians should suspect NF2 in children presenting with meningioma, schwannoma, and skin features, such as neurofibromas/schwannomas, but fewer than 6 café au lait patches, who thus fall short of a diagnosis of neurofibromatosis type 1.

Citing Articles

The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.

Jester N, Singh M, Lorr S, Tommasini S, Wiznia D, Buono F Sci Rep. 2025; 15(1):5918.

PMID: 39966622 PMC: 11836447. DOI: 10.1038/s41598-025-88589-x.

Classification of schwannomas and the new naming convention for "neurofibromatosis-2": Genetic updates and international consensus recommendation.

Rai P, Bathla G, Soni N, Desai A, Rao D, Vibhute P Neuroradiol J. 2025; 19714009251313510.

PMID: 39786185 PMC: 11719429. DOI: 10.1177/19714009251313510.

Neurofibromatosis Type 2 Presenting as Symptomatic Gallbladder Hydrops: A Rare Case Report and Literature Review.

Hafez B, Alwan J, El Hout W, Koussa K, El Annan T, Noun D Case Rep Pediatr. 2024; 2024:7680840.

PMID: 39618887 PMC: 11606685. DOI: 10.1155/crpe/7680840.

Bilateral vestibular schwannoma with a cooccurring meningioma in a child: a case report and review of literature.

Chaulagain R, Shrestha Y, K C K, Baral A Ann Med Surg (Lond). 2024; 86(7):4247-4254.

PMID: 38989221 PMC: 11230781. DOI: 10.1097/MS9.0000000000002217.

Historical Development of Diagnostic Criteria for NF2-related Schwannomatosis.

Tamura R, Yo M, Toda M Neurol Med Chir (Tokyo). 2024; 64(8):299-308.

PMID: 38897938 PMC: 11374461. DOI: 10.2176/jns-nmc.2024-0067.

References

Evans D, Wallace A, Wu C, Trueman L, Ramsden R, Strachan T . Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet. 1998; 63(3):727-36. PMC: 1377392. DOI: 10.1086/512074. View

Evans D, Trueman L, Wallace A, Collins S, Strachan T . Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998; 35(6):450-5. PMC: 1051337. DOI: 10.1136/jmg.35.6.450. View

Kluwe L, Mautner V . Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet. 1998; 7(13):2051-5. DOI: 10.1093/hmg/7.13.2051. View

Wu C, Thakker N, Neary W, Black G, Lye R, Ramsden R . Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas. J Med Genet. 1998; 35(12):973-7. PMC: 1051506. DOI: 10.1136/jmg.35.12.973. View

McGaughran J, Harris D, Donnai D, TEARE D, MacLeod R, Westerbeek R . A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 1999; 36(3):197-203. PMC: 1734324. View

Seizinger B, Rouleau G, Ozelius L, Lane A, Faryniarz A, Chao M . Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell. 1987; 49(5):589-94. DOI: 10.1016/0092-8674(87)90534-4. View

Rouleau G, Wertelecki W, Haines J, Hobbs W, Trofatter J, Seizinger B . Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987; 329(6136):246-8. DOI: 10.1038/329246a0. View

Huson S, Harper P, Compston D . Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988; 111 ( Pt 6):1355-81. DOI: 10.1093/brain/111.6.1355. View

Miyamoto R, Campbell R, Fritsch M, Lochmueller G . Preservation of hearing in neurofibromatosis 2. Otolaryngol Head Neck Surg. 1990; 103(4):619-24. DOI: 10.1177/019459989010300416. View

10.

Evans D, Huson S, Donnai D, Neary W, Blair V, TEARE D . A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992; 29(12):841-6. PMC: 1016198. DOI: 10.1136/jmg.29.12.841. View

11.

Evans D, Huson S, Donnai D, Neary W, Blair V, Newton V . A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet. 1992; 29(12):847-52. PMC: 1016199. DOI: 10.1136/jmg.29.12.847. View

12.

Evans D, Huson S, Donnai D, Neary W, Blair V, Newton V . A clinical study of type 2 neurofibromatosis. Q J Med. 1992; 84(304):603-18. View

13.

Evans D, Ramsden R, Huson S, Harris R, Lye R, King T . Type 2 neurofibromatosis: the need for supraregional care?. J Laryngol Otol. 1993; 107(5):401-6. DOI: 10.1017/s002221510012328x. View

14.

Parry D, Eldridge R, Bouzas E, Pikus A, Patronas N . Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994; 52(4):450-61. DOI: 10.1002/ajmg.1320520411. View

15.

Mautner V, Lindenau M, Baser M, Hazim W, Tatagiba M, Haase W . The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996; 38(5):880-5; discussion 885-6. DOI: 10.1097/00006123-199605000-00004. View

16.

Ruttledge M, Andermann A, Phelan C, Claudio J, Han F, Chretien N . Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996; 59(2):331-42. PMC: 1914741. View

17.

Parry D, MacCollin M, Pulaski K, Nicholson H, Bolesta M, Eldridge R . Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996; 59(3):529-39. PMC: 1914910. View

18.

Kluwe L, Bayer S, Baser M, Hazim W, Haase W, Funsterer C . Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet. 1996; 98(5):534-8. DOI: 10.1007/s004390050255. View

19.

Evans D, Maher E, MacLeod R, Davies D, Craufurd D . Uptake of genetic testing for cancer predisposition. J Med Genet. 1997; 34(9):746-8. PMC: 1051059. DOI: 10.1136/jmg.34.9.746. View

20.

Slattery 3rd W, Brackmann D, Hitselberger W . Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998; 19(5):638-43. View